Organization
Darlinghurst, Australia
3 abstracts
Abstract
Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.Org: NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia, Sydney, Australia, Garvan Institute of Medical Research,
Abstract
Machine learning prediction of patient-reported outcomes associated with systemic therapy from medical records.Org: Garvan Institute of Medical Research, Sydney, Australia, Kinghorn Cancer Centre, Darlinghurst, Australia,
Abstract
Real-world experience of tebentafusp for uveal melanoma via an Australian access program.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, The Kinghorn Cancer Centre, Darlinghurst, Australia,